VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: a Wisconsin Oncology Network study

VcR-CVAD with maintenance rituximab is an intermediate-intensity regimen for older and younger mantle cell lymphoma (MCL) patients. Thirty patients were treated, with primary end point of response and secondary endpoints of progression-free and overall survival. After a median follow-up of 7.8 years, no relapses were observed beyond 6 years. VcR-CVAD has long-term outcomes comparable with more intensive chemotherapy regimens.

Source: Clinical Lymphoma, Myeloma and Leukemia - November 3, 2017 Category: Hematology Authors: J.E. Chang, L.L. Carmichael, K. Kim, C. Peterson, D.T. Yang, A.M. Traynor, J.E. Werndli, M.S. Huie, T.A. McFarland, M. Volk, J. Blank, N.S. Callander, W.L. Longo, Kahl Source Type: research